Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ossirene (AS101) 是一种免疫调节抑制剂,是一种新型 IL-1beta 转化酶抑制剂,可用于自身免疫性疾病和某些恶性肿瘤。它通过抑制IL-10消除 STAT3 的磷酸化,有效抑制Caspase-1。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 195 | 现货 | ||
5 mg | ¥ 476 | 现货 | ||
10 mg | ¥ 675 | 现货 | ||
25 mg | ¥ 1,130 | 现货 | ||
50 mg | ¥ 1,680 | 现货 | ||
100 mg | ¥ 2,480 | 现货 | ||
200 mg | ¥ 3,690 | 现货 |
产品描述 | Ossirene (AS101), a potent in vitro and in vivo immunomodulator, is a novel inhibitor of IL-1beta converting enzyme. |
体外活性 | Treatment of caspase-1 (interleukin-1 [IL-1] converting enzyme [ICE]) with AS101 inhibits its enzymatic activity in a dose-dependent manner. Moreover, AS101 treatment causes a significant reduction in the active form of IL-18 and IL-1 in peripheral blood mononuclear cells (PBMC) and in human HaCat keratinocytes. The inhibitory effect of AS101 does not involve nitric oxide (NO) or interferon- (IFN- ), two possible regulators of IL-18 production, and does not occur at the mRNA level. It may exert effects through a posttranscriptional mechanism[1]. AS101 induced SIRT1 expression in a dose dependent manner in three different cell lines, HEK293, HL-60 and Rin-5f. Incubation of HEK293 and HL-60 cell lines with AS101 (0.1-2.5μg/ml) resulted in a dose dependent reduction in PPARγ protein expression relative to the control cells, and the reduction of PPARγ expression is in parallel to increased SIRT1 expression[2]. |
体内活性 | AS101 downregulates IL-18 and IL-1 serum levels in a mouse model of lipopolysaccharide (LPS)-induced sepsis, resulting in increased survival. It has also been shown to be protective against lethal and sublethal effects of irradiation and chemotherapy. In a model of cecal ligation and puncture (CLP)-induced sepsis in mice, AS101 also exerted beneficial effects[1]. AS101 treated rats showed a large increase in SIRT1 protein levels in the liver and kidney extracts of rats treated with AS101. AS101 prevents development of insulin resistance in vivo. AS101 affects SIRT1 related metabolic pathways by changing the insulin levels. AS101 treatment prevents hyperglycemia associated with T2D(type 2 diabetes) and some of the symptoms of the disease in the HFD(high fat diet)+STZ(Streptozotocin) rat model[2]. |
细胞实验 | In vitro, PBMCs were first treated with various concentrations of AS101, and after 1 h SAC (10-3 v/v) was added. After 24 h, supernatants were collected and evaluated for cytokine content. (Only for Reference) |
别名 | AS101 |
分子量 | 312.05 |
分子式 | C2H4Cl3O2Te·H4N |
CAS No. | 106566-58-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 198.7 mM
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.2046 mL | 16.0231 mL | 32.0461 mL | 80.1154 mL |
5 mM | 0.6409 mL | 3.2046 mL | 6.4092 mL | 16.0231 mL | |
10 mM | 0.3205 mL | 1.6023 mL | 3.2046 mL | 8.0115 mL | |
20 mM | 0.1602 mL | 0.8012 mL | 1.6023 mL | 4.0058 mL | |
50 mM | 0.0641 mL | 0.3205 mL | 0.6409 mL | 1.6023 mL | |
100 mM | 0.032 mL | 0.1602 mL | 0.3205 mL | 0.8012 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Ossirene 106566-58-9 Apoptosis Immunology/Inflammation Proteases/Proteasome IL Receptor Caspase Interleukin RPE NFκB Inhibitor inhibit diseases AS101 immunomodulatory AS-101 autoimmune malignancies tellurium AS 101 IL-6 IL-8 p65 Interleukin Related STAT3 phosphorylation inhibitor